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Abstract 
 
 
Metformin alleviates hepatosteatosis through Sirt1-mediated 
autophagy induction 
 
 
Young Mi Song 
 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
 
(Directed by Professor Bong Soo Cha) 
 
 
Metformin activates both PRKA and SIRT1. Furthermore, autophagy is induced by 
either the PRKA-MTOR-ULK1 or SIRT1-FOXO signaling pathways. We aimed to 
elucidate the mechanism by which metformin alleviates hepatosteatosis by examining 
the molecular interplay between SIRT1, PRKA, and autophagy. ob/ob mice were 
divided into 3 groups: one with ad libitum feeding of a standard chow diet, one with 
300 mg/kg intraperitoneal metformin injections, and one with 3 g/day caloric 
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restriction (CR) for a period of 4 weeks. Primary hepatocytes or HepG2 cells were 
treated with oleic acid (OA) plus high glucose in the absence or presence of 
metformin. Both CR and metformin significantly improved body weight and glucose 
homeostasis, along with hepatic steatosis, in ob/ob mice. Furthermore, CR and 
metformin both upregulated SIRT1 expression and also stimulated autophagy 
induction and flux in vivo. Metformin also prevented OA with high glucose-induced 
suppression of both SIRT1 expression and SIRT1-dependent activation of autophagy 
machinery, thereby alleviating intracellular lipid accumulation in vitro. Interestingly, 
metformin treatment upregulated SIRT1 expression and activated PRKA even after 
siRNA-mediated knockdown of PRKAA1/2 and SIRT1, respectively. Taken together, 
these results suggest that metformin alleviates hepatic steatosis through PRKA-
independent, SIRT1-mediated effects on the autophagy machinery. 
 
 
 
 
 
 
 
 
 
 
Key words: autophagy, hepatoseatosis, metformin, PRKA (protein kinase, AMP-
activated), SIRT1 (sirtuin class of histone/protein deacetylases) 
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I. INTRODUCTION 
 
Efforts for treating non-alcoholic fatty liver disease (NAFLD) have 
traditionally focused on burning excess energy and unloading caloric burdens, on 
either the individual or cellular level. To achieve the aims of increasing energy 
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expenditure and mimicking caloric restriction (CR) in the treatment of metabolic 
disease, a thorough understanding of the molecular machinery involved in these 
processes is required. Understanding how this molecular machinery is dysregulated or 
dysfunctional in NAFLD is also crucial. Although metformin is the first-line anti-
diabetic drug, particularly for overweight and obese people and those with normal 
kidney function, the idea that metformin exerts pleiotropic effects via novel 
mechanisms of action is now gaining popularity.
1,2,3
 In this regard, the mechanism by 
which metformin alleviates hepatosteatosis and the effects of metformin on autophagy 
are two current areas of debate and investigation.  
Autophagy is a conserved cellular process that degrades damaged organelles, 
unfolded proteins and intracellular pathogens by fusion with lysosomes for 
maintenance of cellular homeostasis.
4,5
 Three types of autophagy have been known: 
macroautophagy, chaperone-mediated autophagy (CMA) and microautophagy.
6,7
 
Macroautophagy (hereafter referred to as autophagy) involves the isolation of a 
portion of cytosol by a double membrane structure termed an autophagosome. The 
autophagosome fuses with lysosome resulting in the degradation of the intra-cellular 
components.
6
 In CMA, soluble proteins containing a specific KFERQ motif in their 
amino acids sequence are bound to a chaperone protein for translocation to the 
lysosome, where binding to the lysosome-associated membrane protein type 2A 
(LAMP-2A) receptor results in protein internalization and degradation.
7,8
 The third 
form of autophagy, microautophagy, involves the sequestration of intracellular 
components within lysomes by an invagination of the lysosomal membrane. However, 
these forms of autophagy are little known about the regulation or function.  
As previously mentioned, there are two general functions of autophagy. First, 
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autopahgy can maintain energy homeostasis by generating a source of metabolic 
substrate under limited nutrients. Second, autophagy can also remove damaged 
cellular constituents such as mitochondria and long-lived protein. These functions of 
autophagy sustain cell survival under stress condition.
9-11
 Recent studies have 
suggested that novel function for autophagy is active in the regulation of cellular 
homeostasis such as lipid metabolism and insulin sensitivity.
12,13
 
Liu HY et al. and Yang L et al. have demonstrated that autophagy is impaired in the 
liver in insulin resistant state.
13,14
 In addition, autophagy machinery has been found to 
be associated with lipid metabolism through demonstrating colocalization of lipid 
with autophagosomes and lysosomes assessed by fluorescence microscopy, lipid in 
autophagic vacuoles by electron microscopy , and  an association of the 
autophagosome-associated protein microtubule-associated protein light chain 3 (LC3) 
with lipid droplets by immunogold staining. Furthermore, an inhibition of autophagy 
by either genetic knockdown using siRNA against autophagy gene atg5 or 
pharmacological inhibition with 3-methyladenine (3MA) in hepatocytes which was 
exposed to free fatty acid or methionine and choline-deficient medium, significantly 
increased intracellular TG content.  
In vivo study of mouse livers, hepatocyte-specific atg7, essential autopahgy gene, 
knockout leaded to inhibition of autophagy and consequently increased levels of 
hepatic TGs and cholesterol.
12
  
Taken together, these results suggested autophagy contributed to hepatic lipid stores.
15
 
Subsequently, autophagy inhibition has been reported to induce hepatosteatosis in 
alcohol-induced hepatic injury models as well.
16
 Therefore, autophagy is a central 
mechanism for the lipid droplet breakdown of lipid droplet by lipophagy.
12,17
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The traditional pathways of low nutrition-induced autophagy are either through 
PRKA (protein kinase , AMP-activated)-MTOR-ULK1 mediated signaling, activated 
by an increase in the AMP/ATP ratio, or the sirtuin class of histone/protein 
deacetylases (SIRT1)-FOXO pathway, activated by increased NAD
+
.
18,19
  
Under starvation conditions, active PRKA, which are activated by increase in 
AMP/ATP ratio, positively regulates the activity of the TSC1-TSC2 complex by 
phosphorylating the TSC2 protein (resulting in the opposite activity to the AKT-1 
phosphorylation of TSC2), which then turns off the RHEB G-protein and reduces 
MTOR activity, central regulator in autophagy.
20,21
 MTOR is present in two 
complexes: MTORC1 and MTORC2 (TORC, target of rapamycin complex). 
Inactivation of MTOR allows the dissociation of the MTORC1 complex, leading to 
ULK1 activation, phosphorlatyion of ATG13 and FIP200, and consequently the 
induction of autophagy. The MTORC2 complex is less rapamycin-sensitive.
22,23
  
And CR also stimulates autophagy through the activation of the NAD
+
-dependent 
deacetylases, called sirtuins. SIRT1 can directly deacetylate several essential 
autophagic modulators, such as ATG5, ATG7 and ATG8, thereby inducing 
autophagy.
24
 SIRT1-mediated deacetylation of FOXO1 induces expression of Rab7 
which in turn stimulate autophagy.
25,26
 
Metformin has been reported to mimic the benefits associated with caloric 
restriction.
27,28
 In addition, metformin is well-established to activate both PRKA and 
the NAD
+
-dependent deacetylase SIRT1.
29
 Based on these reports, we aimed to 
elucidate the mechanism by which metformin alleviates NAFLD by investigating the 
molecular interplay between PRKA, SIRT1, and autophagy.  
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II. MATERIALS AND METHODS 
 
1. Animal procedure 
Eight-week-old ob/ob mice (C57bl/6j background, Jackson Laboratory, 
000632) and C57bl/6j control mice (Jackson Laboratory, Bar Harbor, ME, USA) were 
used in this study. ob/ob mice were separated into 3 groups and subjected to the 
following treatment regimens: 1) ad libitum feeding of chow diets (Dyets Inc., 
Bethlehem, PA, USA) and vehicle injection of phosphate-buffered saline (PBS, pH 
7.8; GIBCO, Carlsbad, CA, USA, n=8); 2) ad libitum feeding of chow diets and 
intraperitoneal injections of 300 mg/kg metformin (Merck KGaA, Darmstadt, 
Germany, n=8); and 3) CR group (3 g/day, n=8). Mice were maintained at 60 ± 5 % 
relative humidity and 22 ± 2 °C, with a 12-h light/dark cycle. Mouse weight and food 
intake were measured daily over a 4-week course of treatment. All experimental 
procedures performed in this study followed ethical guidelines for animal studies, and 
were approved by the Institutional Animal Care and Use Committee of Yonsei 
University College of Medicine (IACUC No. 2011-0302-1). 
 
2. Leupeptin assay for measuring autophagic flux  
Mice were intraperitoneally injected with sterile PBS or PBS containing 25 
mg/kg leupeptin hemisulfate (Sigma, St. Louis, MO, USA). After injection, mice were 
returned to their cages and provided water without any food for 5 h.
30
 
 
3. Metabolic and biochemical analyses 
For IPGTTs, 3-week-old mice were fasted overnight and given an 
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intraperitoneal injection of glucose (2 mg/g body weight; Sigma, St. Louis, MO, 
USA). Blood was collected from the tail vein, and glucose concentrations were 
measured at 0, 15, 30, 60, 90, and 120 min using a handheld glucose meter (SD Code 
Free, Standard Diagnostics, Inc., Gyeonggido, Korea). After sacrificing the mice at 4 
weeks, blood was obtained by cardiac puncture, and mouse livers were removed and 
weighed. Serum levels of GOT1/AST (Asan Pharm Inc., Seoul, Korea), GPT/ALT 
(Asan Pharm Inc., Seoul, Korea), and T-CHO were quantified using a commercial kit 
(Asan Pharm Inc., Seoul, Korea).  
 
4. Histological analysis  
After each animal was sacrificed, fresh tissues were immediately frozen and 
subsequently placed in prelabeled base molds filled with embedding medium to 
ensure optimal cutting temperature. Frozen sections (7 µM) were stained with ORO 
(Sigma, St. Louis, MO, USA); paraffin-embedded sections were stained with H&E 
(Dako, Carpinteria, CA, USA). To evaluate hepatic steatosis, morphometric analysis 
was performed on 2 randomly selected fields (at 40× magnification) from a section of 
each animal using an Olympus IX71 microscope equipped with an Olympus DP70 
camera (Olympus Optical Company, Tokyo, Japan). Immunohistochemical analysis 
for the expression of SIRT1 was conducted as previously described.
31
 After epitope 
retrieval by heat in citrate, deparaffinized sections were incubated with anti-SIRT1 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h, rinsed with Tris-
buffered saline (Sigma, St. Louis, MO, USA ) containing 0.1% Tween-20 (Sigma, St. 
Louis, MO, USA), and incubated with a secondary antibody (Vector Laboratories, 
Inc., Burlingame, CA, USA). After washing in PBS, sections were detected with the 
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horseradish peroxidase–conjugated anti-biotin labeling solution (Vector Laboratories, 
Inc., Burlingame, CA, USA). Counterstaining was then performed before examination 
under a light microscope. The sections were mounted and dehydrated permanently in 
nonaqueous mounting medium. The slides were photographed at 20×  and 40×  
magnification) using an Olympus IX71 microscope equipped with an Olympus DP70 
camera.   
 
5. Real-Time PCR  
Total RNA was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer‟s instructions and subjected to reverse 
transcription followed by quantitative real-time PCRs using SuperScript III First-
strand kit (Invitrogen, Carlsbad, CA, USA). cDNA from liver from ob/ob mice was 
used for real-time PCR with SYBR Green (Takara, Shiga, Japan) and run on an 
StepOnePlusTM (Life technologies, Carlsbad, CA, USA) to detect relative mRNA 
levels. The sequences of the primers used for mouse samples were: Acadm, forward 
primer 5‟-TGA CGG AGC AGC CAA TGA-3‟ and reverse primer 5‟-TCG TCA CCC 
TTC TTC TCT GCT T-3‟; Sirt1, forward primer 5-ACC TCC CAG ACC CTC AAG-
3‟ and reverse primer 5‟- TTC CTT CCT TAT CTG ACA AAG C-3‟; Sqstm1, forward 
primer 5‟- GCT GCC CTA TAC CCA CAT CT-3‟ and reverse primer 5‟- CGC CTT 
CAT CCG AGA AAC-3‟; Actb, forward primer 5‟- TGG CGC TTT TGA CTC AGG 
AT -3‟ and reverse primer 5‟- GGG ATG TTT GCT CCA ACC AA -3‟. The sequences 
of the primers used for HepG2 cells were: SQSTM1, forward primer 5‟- CAG GGC 
TGA AGG AAG CTG C-3‟ and reverse primer 5‟-AAG CCC ATG GAC AGC ATC 
TG-3‟; ACTb, forward primer 5‟- TCA TGA AGT GTG ACG TTG ACA TCC GT -3‟ 
10 
 
and reverse primer 5‟- CCT AGA AGC ATT TGC GGT GCA CGA TG -3‟. 
Quantitative analyses were performed using the ΔΔcycle threshold method and 
StepOne Software version 2.2.2. 
 
6. Isolation of primary hepatocyte and cell culture  
Primary mouse hepatocytes were prepared according to the two-step perfusion 
method as previously described
32
 with minor modifications. Livers were digested with 
Hanks‟ balanced salt solution containing 30 μg/mL of Liberase Blendzyme 3 (Roche 
Diagnostics, Indianapolis, IN, USA), 5 mM CaCl2 (Sigma, St. Louis, MO, USA), 0.1 
mg/mL DNaseI (Roche Diagnostics, Indianapolis, IN, USA), and 100 mM HEPES 
(Sigma, St. Louis, MO, USA) for 5 min. After centrifugation, pellets were 
resuspended in growth medium consisting of DMEM (Welgene, Daegu, Korea) 
supplemented with 2.7 mM D-glucose (Sigma, St. Louis, MO, USA) and 10% fetal 
bovine serum and subsequently incubated at 37 °C in humidified air containing 5% 
CO2. After determining cell viability via trypan blue exclusion testing, hepatocytes 
were seeded on collagen-coated 6-well plates (SPL, Gyeonggido, Korea; 5 × 10
5
/well) 
and incubated for 24 h prior to all experiments. HepG2 cells were maintained in 
Dulbecco‟s modified Eagle‟s medium (Welgene, Daegu, Korea) supplemented with 
10% fetal bovine serum and antibiotics. For pharmacological studies, cells were 
incubated with either control (5.5 mM) or high-glucose (30 mM) medium in the 
presence of 1 mM oleic acid (Sigma, St. Louis, MO, USA) after pretreatment with 0.5 
mM metformin for 2 h.  
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7. Quantification of lipids by oil red o staining and triglyceride assay 
Lipid droplets were initially visualized and subsequently quantified by ORO 
staining. Primary mouse hepatocytes and HepG2 cells were exposed to 2 mM and 1 
mM OA, respectively, in the presence of 30 mM glucose after pretreatment with or 
without 0.5 mM metformin, followed by fixation with 10% formalin for 1 h. Fixed 
cells were then stained in prewarmed ORO solution (Sigma, St. Louis, MO, USA ) for 
1 h in a 60 °C water bath, and red-stained lipid droplets were subsequently observed 
with a light microscope. To quantify lipid accumulation, ORO was eluted with 100% 
isopropanol and the optical densities of the eluates were measured using a 
spectrophotometer at 520 nm. TG levels in liver tissue, primary mouse hepatocytes, 
and HepG2 cells were measured with the Triglycerides Quantification Kit (Biovision, 
Mountain view, CA, USA) according to the manufacturer‟s instructions.  
 
8. Plasmid transfection and sirt1 activity assay 
The plasmid construct driving overexpression of SIRT1 was kindly provided 
by Professor Hyun-seok Kim (Ewha Womans University, Seoul, Republic of Korea). 
Transient transfections of plasmid DNA were performed using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer‟s protocol. To 
measure cellular SIRT1 activity, nuclear proteins were extracted from mouse livers, 
primary hepatocytes, and HepG2 cells using a Nuclear/Cytosol Fractionation Kit 
(Pierce Biotechnology, Rockford, IL, USA). SIRT1 activity was quantified with a 
SIRT1 Fluorometric Assay Kit (Sigma, St. Louis, MO, USA) according to the 
manufacturer‟s protocol. Fluorescence intensities were measured with a microplate 
fluorometer (excitation wavelength = 360 nm, emission wavelength = 450 nm).  
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9. RNA interference 
Primary hepatocytes and HepG2 cells were transfected with siRNAs targeting 
ATG5 (Sigma, St. Louis, MO, USA), SIRT1 (Sigma, St. Louis, MO, USA), 
PRKAA1/2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or a control siRNA 
(Sigma, St. Louis, MO, USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, 
USA) by following the manufacturer‟s instructions. Cells were incubated for 16 h 
with a transfection mixture containing a final siRNA concentration of 100 pM, and 
then supplemented with fresh medium. 
 
10. Immunoblotting and antibodies 
Mouse livers, primary hepatocytes and HepG2 cells were lysed in PRO-PREPTM 
protein extraction solution (iNtRON Biotechnology, 17081), and the protein contents 
of the resulting lysates were measured with the Bradford assay (Bio-Rad, Hercules, 
CA, USA). Equal amounts of proteins were resolved by SDS-PAGE and 
electroblotted onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). 
Membranes were subsequently probed as indicated with the following primary 
antibodies: LC3B (Cell Signaling Technology, Danvers, MA, USA), PRKA (Cell 
Signaling Technology, Danvers, MA, USA), pPRKA (Cell Signaling Technology, 
Danvers, MA, USA), pACAC (Cell Signaling Technology, Danvers, MA, USA), 
SIRT1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). 
 
11. Detection of autophagy   
To monitor autophagy, levels of conversion of the autophagy marker protein 
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MAP1LC3/LC3 (microtubule-associated protein 1 light chain 3)-I to LC3-II were 
measured by immunoblotting. Detection of autophagosomes was also performed by 
transfecting HepG2 cells with a plasmid driving the expression of GFP-LC3 
(ORIGINE Technologies, Inc., Rockville, MD, USA). Transfected cells were fixed 
with 4% paraformaldehyde and then observed with a confocal microscope. Cells were 
classified as having either a predominantly diffuse GFP stain, or as having numerous 
punctate structures representing autophagosomes. To assay autophagic flux, LC3 
processing either in the presence or absence of 50 μM of the lysosomal alkalinizing 
agent, CQ (Sigma, St. Louis, MO, USA), was assayed by immunoblotting. For 
detection of autophagosomes using electron microscopy, liver tissues of ob/ob mice 
were fixed with 2% glutaraldehyde-2% paraformaldehyde buffered with 0.1 M 
phosphate buffer (pH 7.2) overnight at 4 °C, post-fixed with 1% osmium tetroxide in 
a 0.1 M sodium cacodylate buffer (pH 7.4) for 1 h at room temperature, and were 
dehydrated with a graded series of ethanol as previously described.
8
 The dehydrated 
tissues were then embedded in Epon, poly/Bed812 Embedding kit/DMP-30 
(Polysciences, Warrington, PA, USA). Sectioning for electron microscopy 
examination was accomplished with an ultramicrotome (Leica, Wetzlar, Germany), 
and electron microscopy was performed with a JEM-1011 transmission electron 
microscope (JEOL, Peabody, MA, USA). Autophagic vacuoles were counted from at 
least 20 random cells, averaged and expressed as the number of autophagic vacuoles 
per cell. 
 
12. Statistical analysis 
Statistical analysis was performed using PRISM (GraphPad Software Inc., San 
14 
 
diego, CA, USA). Results are expressed as means ± SE, and statistical significance 
was calculated using Student‟s t-test. Alternatively, for comparisons involving more 
than 2 groups, one-way analysis of variance (ANOVA) with a post hoc Bonferroni 
multiple comparison test was used to assess the differences between the groups. 
Differences in liver weights among 4 mice groups were compared by using analysis 
of covariance (ANCOVA) with adjustment for body weights. Statistical significance 
was defined as the conventional p value of <0.05. 
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III. RESULTS  
 
1. Metformin and caloric restriction decrease body weight and blood glucose 
in ob/ob mice 
To confirm the reported beneficial metabolic phenotypes of metformin 
treatment and CR in vivo, body weight and gluco-metabolic parameters were assessed 
in C57bl/6j control and ob/ob mice through weekly fasted blood glucose 
measurements and intraperitoneal glucose tolerance tests (IPGTTs). The ob/ob mouse, 
an animal model of obesity and type 2 diabetes, eats excessively and expresses 
mutation in the gene encoding leptin, which is important in the control of appetite. 
Despite increased levels of insulin, ob/ob mice develop high blood glucose.
33
 Whole 
body weights of ob/ob mice treated with 3 g/day CR (p<0.001 at 1, 2, 3, and 4 weeks) 
and 300 mg/kg metformin (p<0.01 at 1 and 2 weeks, p<0.05 at 4 weeks) were 
significantly lower than those fed ad libitum (Fig. 1A). Except for ob/ob mice treated 
with CR (all p<0.001), food intakes were not different among ob/ob mice (Fig. 1B). 
As shown in Fig. 1C, blood glucose levels in the fasting condition were significantly 
decreased throughout the entire experiment by metformin treatment (p<0.05 at 1 week; 
p<0.01 at 2, 3 weeks; p<0.001 at 4 weeks) and CR treatment (p<0.001) compared 
with ad libitum-fed mice, whose blood glucose levels ranged from 300 to 400 mg/dL 
at 2 weeks post-ad libitum. To investigate the effect of metformin treatment and CR 
on glucose tolerance, we performed 2 g/kg body weight IPGTTs at 3 weeks (Fig. 1D). 
Compared to ad libitum-fed mice, tolerances to glucose loading were significantly 
improved in CR-treated mice at all-time points tested (p<0.001) and in metformin-
treated mice at 60, 90, and 120 min (p<0.05, p<0.01, and p<0.01, respectively).  
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
ob/ob 
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Figure 1. Metabolic effects of metformin and caloric restriction on ob/ob mice. 
(A) The effects of metformin and CR on body weight, (B) food intake, and (C) blood 
glucose in the 8-week-old C57bl/6j control (○) and ob/ob mice were evaluated. The 
latter mice were classified into 3 groups: ad libitum feeding of chow diets (▲), 300 
mg/kg intraperitoneal metformin (△), and 3 g/day CR (●). (A) During a 4-week 
treatment course of either metformin or CR, body weight significantly decreased 
compared to ad libitum-fed ob/ob mice. (B) Due to the protocol of this study, food 
intake was only reduced in calorie-restricted mice. (C) Blood glucose levels were 
significantly decreased throughout the entire 4 weeks in ob/ob mice treated either 
with metformin or CR, compared to ad libitum-fed ob/ob mice. (D) At 3 weeks, 
glucose tolerance tests were performed after an intraperitoneal injection of glucose (2 
g/g body weight). Blood was collected from the tail vein, and glucose concentrations 
were measured at 0, 15, 30, 60, 90, and 120 min. CR significantly improved glucose 
tolerance throughout the IPGTTs, but metformin only significantly improved glucose 
tolerance at 60, 90, and 120 min. Values displayed are means ± SEM of 8 mice per 
group. 
***
p < 0.001, CR vs. ad libitum-fed ob/ob mice; 
†
p < 0.05, 
††
p < 0.01, and 
†††
p < 
0.001, metformin vs. ad libitum-fed ob/ob mice. 
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2. Metformin and caloric restriction alleviate liver dysfunction and hepatic 
lipid accumulation in ob/ob mice 
To examine whether metformin and CR alleviated hepatic fat accumulation 
in vivo, serum levels for total cholesterol (T-CHO), GOT1/AST (glutamic-oxaloacetic 
transaminase 1, soluble), and GPT/ALT, [glutamic-pyruvate transaminase (alanine 
aminotransferase)], as well as triglyceride (TG) contents and hepatic histology were 
evaluated in C57bl/6j control and ob/ob mice. Serum levels of T-CHO were 
significantly reduced in both the CR- (97.3±10.4, p<0.01) and metformin-treated 
groups (101.9±8.9, p<0.01) compared to the ad libitum-fed group (122.8±15.6 mg/dL, 
Fig. 2A). The elevated GOT1 and GPT serum levels of the ad libitum-fed group 
(37.74±5.49 and 33.53±5.15, respectively) were significantly lowered by treatment 
with CR (19.54±1.28 and 17.09±3.26, both p<0.05) and metformin (21.95±3.07 and 
18.74±3.82, both p<0.05, respectively; Fig. 2B and C). As shown in Fig. 2D, liver 
weights adjusted by body weights in the CR- (1.53±0.15 g, p<0.05) and metformin-
treated groups (2.20±0.16 g, p<0.001) were significantly lower than those in the ad 
libitum-fed group (2.88±0.35 g). Compared to the ad libitum-fed mice (3.89±0.49 
TG/protein nm/μg), CR- (0.85±0.06, p<0.001) and metformin-treated mice 
(2.13±0.70, p<0.05) showed a significant decrease in hepatic TG contents as assessed 
by a Quantification Colorimetric Kit (Fig. 2E). Liver sections were also stained with 
hematoxylin and eosin (H&E,× 40) to visualize lipid accumulation under all treatment 
conditions. Extensive macrovesicular steatosis surrounding the perisinusoidal areas 
was present in ad libitum-fed ob/ob mice. However, visible decreases in the 
accumulation of intracellular lipid droplets were observed in ob/ob mice upon 
treatment with both metformin and CR (Fig. 2F). 
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Figure 2. Hepatic effects of metformin and caloric restriction on ob/ob mice. (A-
C) Serum chemistry values, (D-F) as well as TG contents and hepatic histology, were 
evaluated after 4 weeks of metformin administration or CR. (A-C) Levels of T-CHO, 
as well as GOT1 and GPT activity, were significantly decreased in ob/ob mice treated 
with metformin or CR compared to ad libitum-fed ob/ob mice. Mice treated with 
either metformin or CR also showed a significant decrease both in (D) liver weights 
adjusted by body weights and also in (E) hepatic fat accumulation compared to ad 
libitum-fed ob/ob mice. (F) Staining of liver sections with H&E (x 40) revealed 
extensive macrovesicular steatosis around the perisinusoidal area in ad libitum-fed 
ob/ob mice. Values displayed are means ± SEM of 8 mice per group. Asterisks (
*
p < 
0.05, 
**
p < 0.01, 
***
p < 0.001) indicate significant differences compared to ad libitum-
fed ob/ob mice.  
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3. Metformin reduces oleic acid-induced lipid accumulation in hepatocytes in 
vitro 
To confirm the lipid clearance effects of metformin on primary mouse 
hepatocytes in vitro, we stained lipid droplets with Oil Red O (ORO) and measured 
TG with Triglycerides Quantification Kit (Fig. 3A); furthermore, we also quantified 
TGs in HepG2 cells via spectrophotometry (Fig. 3B). As shown in Fig. 3, treatment 
with 2 mM OA for primary hepatocytes (0.021±0.004 vs. 0.028±0.002, p<0.01) and 1 
mM OA for HepG2 cells (0.27±0.01 vs. 0.36±0.005, p<0.001) significantly increased 
intracellular lipid accumulation in the presence of 30 mM glucose for 8 h. However, 
pretreatment with 0.5 mM metformin significantly attenuated OA-induced lipid 
accumulation in both primary mouse hepatocytes (0.028±0.002 vs. 0.022±0.004, 
p<0.05) and HepG2 cells (0.36±0.005 vs. 0.29±0.01, p<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Metformin reduces oleic acid-induced lipid accumulation in 
hepatocytes in vitro. Treatment with OA (2.0 mM for primary hepatocytes, 1.0 mM 
for HepG2 cells) in combination with 30 mM glucose for 8 h significantly increased 
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intracellular lipid accumulation. In contrast, pretreatment with 0.5 mM metformin for 
2 h before OA exposure significantly reduced OA-induced lipid accumulation in both 
primary (A) hepatocytes and (B) HepG2 cells, as assessed by visualization and 
quantification of ORO staining (x 40). Values displayed are means ± SEM of 8 
independent experiments. Asterisks (
*
p < 0.05, 
**
p < 0.01, 
***
p < 0.001) indicate 
significant differences. 
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4. SIRT1 expression and induction of autophagy are suppressed in type 2 
diabetic ob/ob mice, but are ameliorated by metformin 
SIRT1 regulates autophagy by deacetylating autophagy machinery, including 
the autophagic players ATG5, ATG7, and LC3. To test the hypothesis that hepatic 
SIRT1 expression and autophagy induction are suppressed in type 2 diabetes, and that 
restoration of SIRT1 expression and autophagy induction can be achieved by 
treatment with metformin and CR in the ob/ob mouse model of type 2 diabetes, 
SIRT1 and autophagy induction were evaluated in this model. Compared to C57bl/6j 
mice, downregulated hepatic expression of SIRT1 protein as well as mRNA and 
SIRT1 activity were observed in C57bl/6j background ob/ob mice, while SIRT1 
expression and activity were restored in ob/ob mice treated with a 4-week course of 
CR or metformin (Fig. 4A). With respect to autophagy, LC3-I to LC3-II conversion 
were significantly increased, while expression of SQSTM1 was decreased in ob/ob 
mice treated with a 4-week course of CR or metformin compared to those fed ad 
libitum (Fig. 4B).  
To verify autophagic flux under the in vivo condition, leupeptin was administrated 
into each mouse before sacrifice and the rate of LC3-II accumulation after leupeptin 
injection was calculated from immunoblots (Fig. 4C). Consistent with in vitro 
findings, this leupeptin-based assay demonstrated that leupeptin treatment 
significantly increased the amount of LC3-II accumulation (designated as LC3 net 
flux) in ob/ob mice treated with CR or metformin compared to ad libitum-fed mice.  
Furthermore, autophagosomes and autolysosomes were determined in the liver tissue 
of each group using an electron microscope to support the evidence of autophagy 
induction (Fig. 4D). Hepatocytes in ob/ob mice treated with a 4-week course of CR or 
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metformin had a significantly increased number of autophagic vacuoles compared 
with those fed ad libitum.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
29 
 
 
 
 
Figure 4. SIRT1 expression and autophagy induction are decreased in ob/ob mice. 
(A) Immunoblots, SIRT1 activity assay and real time PCR and immunohistochemistry 
for SIRT1 were performed in mice liver tissues. Hepatic expression and activity of 
SIRT1 and induction of autophagy were significantly decreased in ad libitum-fed 
ob/ob mice, compared to C57bl/6j control mice. Furthermore, a 4-week treatment 
course of either metformin or CR significantly restored the expression and activity of 
SIRT1 and induction of autophagy in ob/ob mice. (B) Expression of LC3 and 
SQSTM1 was shown as a densitometric graph of the optical density-based data of 
immunoblots. (C) LC3 immunoblots were conducted in liver tissues from 4 
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experimental groups to analyze autophagy flux in vivo using a leupeptin-based assay. 
Autophagy flux was expressed as the subtraction of the amount of LC3-II in the 
absence of leupeptin from the amount of LC3-II in the presence of leupeptin for each 
of the conditions, (C, right graph) which is defined as “LC3 net flux” and graphically 
displayed. (D) Autophagosomes (red arrows) and autolysosomes (white arrows) were 
shown in the electron microscopy images from ad libitum-fed ob/ob mice and ob/ob 
mice treated with CR or metformin. Scale bars are indicated. (D, right graph) The 
numbers of autophagic vacuoles (autophagosomes and autolysosomes) per cell (n=20) 
were counted and graphically displayed. Values displayed are means ± SEM of at 
least 5 independent experiments. Asterisks (
*
p < 0.05, 
**
p < 0.01 and 
***
p < 0.001) 
indicate significant differences.  
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5. Oleic acid suppresses hepatic expression of SIRT1 and autophagy 
induction, but metformin restores SIRT1 expression and activates the autophagy 
machinery 
To test the possible mechanisms by which a dysfunctional autophagic pathway 
results in lipid accumulation, and functional autophagy mediates lipid clearance, the 
integrity of the autophagy machinery was assessed on several levels. First, we 
demonstrated OA-induced suppression of SIRT1 in both a dose- (0, 0.1, 0.5, 1.0 mM) 
and time- (0, 3, 6, 9, 12, 24 h) dependent manner in both HepG2 cells and primary 
hepatocytes (Fig. 5Ai and Aii). Second, we employed multiple techniques to 
demonstrate OA-induced dysfunctional autophagy in vitro. Dysfunctional autophagy 
was first validated with autophagic flux assays; as shown in Fig. 5B, 1.0 mM OA in 
the presence of 30 mM glucose suppressed conversion of LC3-I to LC3-II (designated 
as LC3 net flux), compared to the control group. Next, we employed fluorescence 
confocal microscopy to visualize autophagosome formation. HepG2 cells and primary 
hepatocytes ectopically expressing GFP-LC3 exhibited a decrease in the number of 
punctate GFP-LC3 structures upon exposure to 1.0 mM OA, either in the presence or 
absence of 50 µM chloroquine (CQ; Fig. 5Ci and Cii).  
Then, we examined metformin-induced upregulation of SIRT1 expression and 
autophagy induction in vitro. As shown in Fig. 6A, HepG2 cells and primary 
hepatocytes exposed to different concentrations of metformin (0, 0.1, 0.5, 1.0 mM) 
showed significantly increased activity and expression of SIRT1, in a dose-dependent 
manner. Metformin also upregulated the expression of phosphorylated PRKA 
(pPRKA) and pACAC (phosphorylated acetyl-CoA carboxylase) in a dose-dependent 
manner (Fig. 6A). Consistent with these findings in vitro, both metformin and CR 
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significantly induced mRNA expression of the gene encoding ACADM (acyl-CoA 
dehydrogenase, C-4 to C-12 straight chain), one of the key enzyme in the β-oxidation 
pathway
34
 in liver tissues compared with those fed ad libitum (Fig. 6B). In autophagy 
flux assays, increased conversion of LC3-I to LC3-II and reduction of SQSTM1 
expression were observed in both metformin-treated HepG2 cells and primary 
hepatocytes (Fig. 6C). This increase in LC3 net flux and decrease in SQSTM1 
expression occurred in a dose-dependent manner. In addition, electron microscopy 
analysis showed that the numbers of autophagosomes and autolysosomes were 
significantly increased after metformin treatment in hepatocytes (Fig. 6D).  
Furthermore, pretreatment with 0.5 mM metformin prevented OA-induced 
suppression of SIRT1 expression and LC3-II conversion (Fig. 7A). An autophagic 
flux assay using CQ showed that the conversion of LC3-I to LC3-II was blocked in 
OA-treated hepatocytes, but was restored after metformin treatment. In addition, 
increased expression of SQSTM1 by OA was significantly reduced after metformin 
pretreatment. To test the hypothesis that metformin reduces lipid accumulation by 
inducing autophagy, we inhibited the induction of autophagy with either siRNA 
directed against ATG5, or a pharmacological inhibitor of autophagy, 3-methyladenine 
(3MA). Intracellular lipid accumulation in HepG2 cells and primary mouse 
hepatocytes was analyzed by using a spectrophotometer at 520 nm and a colorimetric 
quantification kit, respectively (Fig. 7B-D). While 1.0 mM OA significantly increased 
the lipid contents of HepG2 cells (0.17±0.003 vs. 0.37±0.01, p<0.001), 0.5 mM 
metformin significantly decreased intracellular fat loading (0.37±0.01 vs. 0.34±0.01, 
p<0.05). However, after siRNA-mediated knockdown of ATG5, metformin no longer 
attenuated OA-induced lipid accumulation (0.39±0.01 vs. 0.37±0.003, p=0.15; Fig. 
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7B). Similarly, metformin was also unable to attenuate OA-induced lipid 
accumulation in the presence of 5 mM 3MA in both HepG2 cells (0.11±0.003 vs. 
0.12±0.002, p=0.08; Fig. 7C) and primary mouse hepatocytes (0.029±0.001 vs. 
0.03±0.001, p=0.61; Fig. 7D). 
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Figure 5. Oleic acid downregulates hepatic expression of SIRT1 and suppresses 
autophagy machinery. (Ai and Aii designated as HepG2 cells and primary 
hepatocytes, respectively) HepG2 cells and primary hepatocytes exposed to OA in 
combination with 30 mM glucose exhibited decreased levels of SIRT1, as assessed by 
immunoblots, in a dose- (0, 0.1, 0.5 and 1.0 mM OA) and time- (0, 3, 6, 9, 12, and 24 
h) dependent manner. (Bi and Bii) Furthermore, treatment with the lysosomal 
inhibitor CQ (50 µM) in combination with 1.0 mM OA and 30 mM glucose decreased 
LC3-II conversion, whereas CQ alone upregulated LC3-II levels in LC3 immunoblot 
flux assays. Autophagy flux was expressed as the subtraction of the amount of LC3-II 
in the absence of CQ from the amount of LC3-II in the presence of CQ for each of the 
conditions, which is defined as “LC3 net flux” and graphically displayed. (Ci and Cii) 
Fluorescence confocal microscopy was used to monitor the vesicle formation step of 
autophagy and autophagosome-lysosome fusion in the absence or presence of 50 µM 
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CQ. The number of GFP-LC3 puncta was quantified and plotted. Punctate patterns of 
the autophagic marker GFP-LC3 were decreased in response to autophagic inhibition 
by 1.0 mM OA. Asterisks (
**
p < 0.01 and 
***
p < 0.001) indicate significant differences.  
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Figure 6. Metformin upregulates SIRT1 and stimulates induction of autophagy. 
Metformin upregulated the expression and activity of SIRT1, phosphorylated PRKA 
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(pPRKA), and phosphorylated ACAC (pACAC) in a dose-dependent manner, as 
shown by immunoblots from (Ai) HepG2 cells and (Aii) primary hepatocytes. 
Asterisks (
*
p < 0.05 and 
**
p < 0.01) indicate significant differences compared to the 
no-metformin control. (B) Real-time RT-PCR of Acadm (acyl-CoA dehydrogenase, C-
4 to C-12 straight chain) expression in mouse livers showed that CR and metformin 
treatment significantly increased the level of Acadm. (Ci and Cii) In LC3 flux assays, 
metformin increased LC3-II expression in a dose-dependent manner (0, 0.1, and 0.5 
mM), and CQ (50 µM) upregulated LC3-II conversion in HepG2 cells and primary 
hepatocytes, as assessed by immunoblots. Autophagy flux was expressed as the 
subtraction of the amount of LC3-II in the absence of CQ from the amount of LC3-II 
in the presence of CQ for each of the conditions, which is defined as “LC3 net flux” 
and graphically displayed. Expression of SQSTM1 was decreased in metformin-
treated cells in a dose-dependent manner, while it increased after addition of CQ (50 
µM). (D) In transmission electron microscopy images, the number of autophagosomes 
(red arrows) and autolysosomes (white arrows) were significantly increased in 
primary hepatocytes treated with metformin compared with controls. Scale bars are 
indicated. (D, right graph) The numbers of autophagic vacuoles (autophagosomes and 
autolysosomes) per cell (n=20) were counted and graphically displayed.  
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Figure 7. Metformin reduced OA-induced lipids by autophagy induction. (A) 
Metformin also inhibited OA-induced downregulation of SIRT1 expression and 
autophagy induction. (Ai) HepG2 cells and (Aii) primary hepatocytes exposed to 1.0 
mM OA showed a significant decrease in SIRT1 expression and autophagy induction, 
whereas pretreatment with 0.5 mM metformin significantly reduced OA-induced 
autophagy dysfunction. Expression of indicated proteins was shown as a 
densitometric graph of the optical density-based data of immunoblots. Furthermore, 
LC3 immunoblot flux assays showed that treatment with the lysosomal inhibitor CQ 
(50 µM) in combination with 1.0 mM OA alone decreased LC3-II conversion, 
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whereas treatment with 0.5 mM metformin in the presence of CQ increased LC3-II 
expression in both HepG2 cells and primary hepatocytes regardless of OA. 
Autophagy flux was expressed as the subtraction of the amount of LC3-II in the 
absence of CQ from the amount of LC3-II in the presence of CQ for each of the 
conditions, which is defined as “LC3 net flux” and graphically displayed. (B-D) Lipid 
accumulation was determined by fat quantification in the presence or absence of the 
autophagic inhibitor 3MA, and also after siRNA-mediated knockdown of ATG5. OA-
treated primary mouse hepatocytes and HepG2 cells exhibited a significant increase in 
lipid accumulation. However, treatment with 0.5 mM metformin significantly 
decreased the OA-induced intracellular lipid accumulation. Furthermore, the lipid 
contents of both HepG2 cells transfected with (B) siRNA against ATG5 and (C) 
HepG2 cells or (D) primary hepatocytes treated with 5 mM 3MA in the presence of 
metformin and OA were similar to those of cells treated with OA alone. Values 
displayed are means ± SEM of 5 independent experiments. Asterisks (
*
p <0.05, 
**
p < 
0.01 and 
***
p < 0.001) indicate significant differences. 
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6. Metformin activates SIRT1 expression through a PRKA-independent 
pathway 
To determine whether metformin induced SIRT1 expression through a PRKA-
independent pathway, siRNAs directed against PRKAA1/2 or SIRT1 were transfected 
into HepG2 cells. Metformin upregulated SIRT1 activity as well as its expression, 
regardless of PRKA expression levels (Fig. 8A). With respect to autophagy, 
metformin significantly increased the level of LC3-II, while it decreased SQSTM1 
expression in both PRKA-sufficient and -deficient conditions. In Fig. 8B, metformin 
treatment significantly reduced lipid accumulation in OA-treated HepG2 cells 
regardless of the presence of PRKA. Interestingly, the amount of lipid was much 
lower in OA and metformin co-treated cells transfected with control siRNA compared 
to those with PRKAA1/2 siRNA (0.337±0.01 vs. 0.359±0.005, p<0.05). After 
transfection with siRNA against SIRT1, SIRT1 knockdown did not interfere with 
metformin-induced phosphorylation of PRKA (Fig. 8C).   
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Figure 8. Metformin upregulates SIRT1 expression through a PRKA-
independent pathway. (A) HepG2 cells were transfected with siRNA against 
PRKAA1/2 or a scrambled siRNA control. Densitometric graphs of the optical 
density-based data of immunoblots showed that SIRT1 expression and activity were 
significantly upregulated after metformin treatment in HepG2 cells regardless of 
PRKA expression levels. Metformin also decreased SQSTM1 expression while it 
increased LC3-II levels in both control and PRKAA1/2 siRNA-treated cells. (B) Oil 
Red O staining and spectrophotometer analysis of HepG2 cells transfected with either 
siRNA against PRKAA1/2 or scrambled siRNA control demonstrated that metformin 
significantly decreased lipid accumulation in cells treated with OA. (C) HepG2 cells 
were then transfected with siRNA against SIRT1, and a scrambled siRNA control, 
showing that the ratio of pPRKA and PRKA expression was increased upon treatment 
with metformin regardless of SIRT1 levels. Values displayed are means ± SEM of 3 to 
6 independent experiments. Asterisks (
*
p <0.05, 
**
p < 0.01 and 
***
p < 0.001) indicate 
significant differences.  
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7. SIRT1 attenuates lipid accumulation in hepatocytes through SIRT1-
mediated autophagy induction 
To confirm that SIRT1-mediated autophagy induction was responsible for 
hepatic lipid clearance, either a vector driving SIRT1 overexpression or siRNA 
directed against SIRT1 were transfected into HepG2 cells. As shown in Fig. 9A and B, 
the SIRT1 vector increased SIRT1 expression, decreased SQSTM1 levels and 
promoted subsequent conversion of LC3-II, whereas SIRT1 siRNA downregulated 
SIRT1 expression, increased SQSTM1 levels and decreased the conversion of LC3-II. 
OA-induced lipid accumulation was significantly alleviated by transfecting the SIRT1 
vector into both HepG2 cells (0.019±0.0007 vs. 0.015±0.0005, p<0.05; Fig. 9C) and 
primary hepatocytes (0.011±0.001 vs. 0.008±0.0005, p<0.05; Fig. 9D). To elucidate 
whether hepatic lipid clearance required the SIRT1-mediated autophagy pathway, we 
disrupted this pathway through both siRNA knockdown of SIRT1 expression and the 
pharmacological inhibitor 3MA. Intracellular lipid accumulation in HepG2 cells and 
primary mouse hepatocytes were analyzed using a spectrophotometer at 520 nm and a 
colorimetric quantification kit, respectively. While 2 mM OA significantly increased 
the lipid contents in HepG2 cells (0.28±0.007 vs. 0.4±0.02, p<0.05), 0.5 mM 
metformin significantly decreased this intracellular fat loading (0.4±0.02 vs. 
0.35±0.008, p<0.05). However, upon siRNA-mediated SIRT1 knockdown, metformin 
was unable to attenuate OA-induced lipid accumulation (0.41±0.007 vs. 0.39±0.008, 
p=0.11) in HepG2 cells (Fig. 9E). Similarly, after siRNA-mediated SIRT1 knockdown 
in primary mouse hepatocytes, metformin also did not attenuate 1 mM OA-induced 
lipid accumulation (0.012±0.0008 vs. 0.01±0.0007, p=0.54, Fig. 9F). In the absence 
of 5 mM 3MA, 1 mM OA-induced lipid accumulation was significantly attenuated by 
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overexpression of SIRT1 (0.017± 0.0017 vs. 0.012±0.0006, p<0.05). However, in the 
presence of 5 mM 3MA, OA-induced lipid accumulation was not alleviated by SIRT1 
overexpression (0.017±0.0013 vs. 0.016±0.0011, p=0.76, Fig. 9G).  
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Figure 9. SIRT1 attenuates lipid accumulation in hepatocytes through SIRT1-
mediated induction of autophagy. (A) Increased protein levels of SIRT1 in HepG2 
cells transfected with a SIRT1 vector increased LC3-II conversion, while decreased 
expression of SQSTM1 was verified by immunoblots. Expression ratio of 
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pPRKA/PRKA was also increased in SIRT1 overexpression cells. (B) Furthermore, 
transfection with siRNA against SIRT1 decreased both SIRT1 protein levels and also 
conversion of LC3-I to LC3-II. Expression of SQSTM1 was significantly increased, 
while pPRKA levels were not affected. To investigate whether SIRT1 could regulate 
lipid accumulation in hepatocytes, either a SIRT1 overexpression vector or siRNA 
directed against SIRT1 were transfected into HepG2 cells and primary mouse 
hepatocytes. In (C) HepG2 cells and (D) primary hepatocytes, OA-induced increases 
in intracellular TG contents were significantly reduced by SIRT1 overexpression. In 
accordance with the data presented in Fig. 6D, OA-induced intracellular lipid 
accumulation was significantly alleviated by metformin treatment of control siRNA-
treated (E) HepG2 cells and (F) primary hepatocytes. In contrast, reduction of lipid 
contents by metformin was negligible in SIRT1-knockdown cells. (G) Lipid 
accumulation was also examined in the presence or absence of the autophagic 
inhibitor 3MA. OA-treated HepG2 cells exhibited a significant increase in lipid 
accumulation. However, SIRT1 overexpression significantly decreased OA-induced 
intracellular lipid accumulation. Lipid contents of cells treated with 5 mM 3MA and 
transfected with SIRT1 were similar to those of cells treated with OA alone. Values 
are displayed as means ± SEM of 8 mice per group. Asterisks (
*
p < 0.05, 
**
p < 0.01, 
***
p < 0.001) indicate significant differences.  
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Figure 10. Summary of working thesis of the study (See the text for details).  
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IV. DISCUSSION 
 
Autophagy facilitates the removal of damaged proteins and aged organelles, 
thereby maintaining cellular homeostasis. Under conditions of nutrient deprivation, 
induction of autophagy provides a simple response for cells to reutilize their own 
constituents for energy.
35,36
 From a translational point of view, nutritional deprivation 
through CR causes weight reduction on the individual level, and induces autophagy 
on the cellular level. Similar to CR, metformin causes weight reduction and induces 
autophagy through PRKA activation.
27,28,37-40
 Metformin belongs to the biguanide 
class of drugs and inhibits complex I of the electron transport chain by sequentially 
lowering the cellular energy charge and then activating PRKA.
41,42
 In this regard, 
lifestyle modification through CR and taking metformin are thought to induce 
autophagy; a promising approach for treating NAFLD.
35,12,17,43,44
 Based on these 
reports, we used an animal model to implement CR as a lifestyle modification, and 
metformin as a drug therapy in both cellular and animal models. 
The traditional role of PRKA is to act as a cellular stress and energy sensor, and its 
activity increases upon glucose deprivation.
37
 It is also well established that PRKA 
can cooperate with the fuel/NAD
+
-dependent sirtuin class of histone/protein 
deacetylases (SIRTs). SIRT1 has been reported to mediate the beneficial metabolic 
effects of CR through deacetylation of transcription factors such as PPARG 
(peroxisome proliferator-activated receptor gamma), PPARA, PPARGC1A 
(peroxisome proliferator-activated receptor gamma, coactivator1 alpha) and FOXO 
(forkhead box O). These transcription factors are involved in diverse processes such 
as hepatic lipid metabolism, gluconeogenesis, mitochondrial biogenesis, and energy 
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expenditure.
45-48
 Particularly, liver-specific SIRT1 deletion induces hepatic steatosis 
and inflammation via impairment of PPARA signaling.
48
 Conversely, both PRKA and 
SIRT1 are downregulated in the liver under stress conditions of nutrient excess, 
including a high-fat diet, obesity, and type 2 diabetes.
45,15,49
 In addition, SIRT1-
deficient mice exhibit a premature aging phenotype and develop fatty livers.
48,50,51
 
Based on these reports, we investigated the molecular interplay between SIRT1, 
PRKA, and autophagy in response to metformin. 
The present study aimed to determine whether metformin alleviates hepatosteatosis 
through SIRT1-mediated autophagy induction, and whether this mechanism is PRKA-
independent. This work had 3 main findings: First, SIRT1 expression and induction of 
autophagy are significantly downregulated both in the livers of ob/ob mice and also in 
OA- plus 30 mM glucose-treated hepatic cell lines. Second, both CR and metformin 
treatment caused weight reduction and alleviated hepatosteatosis and glucose 
homeostasis in ob/ob mice in association with increasing SIRT1 expression and 
induction of autophagy. Third, metformin treatment restored SIRT1 expression and, 
consequently, induction of autophagy, via a PRKA-independent pathway.  
Regarding the effects of metformin on hepatosteatosis, definitive evidence that 
metformin is the treatment option of choice for fatty livers in humans is still lacking. 
Even taking into account the comorbidities of NAFLD with other diseases such as 
obesity, glucose intolerance and dyslipidemia, the primary cause of lipid 
accumulation in the liver is not yet clear. An increased supply of free fatty acids, de 
novo hepatogenic lipogenesis, decreased oxidation of free fatty acids, and secretion of 
hepatic very-low-density lipoprotein-triglycerides have all been implicated in the 
development of NAFLD.
30,35,52
 The need to develop a new model of the molecular 
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pathways responsible for NAFLD has generated intense interest in autophagy as a 
pathway that could be manipulated for the management of NAFLD.
12,35
 Here, we used 
the ob/ob mouse model, which mimics type 2 diabetes, to show that these mice 
exhibited increased body weight, an accumulation of hepatic fat, decreased hepatic 
levels of SIRT1, and suppressed autophagic machinery when fed ad libitum. However, 
metformin treatment of these mice caused significant weight reduction and alleviated 
hepatic lipid accumulation. In vitro experiments with both primary hepatocytes and 
HepG2 cells were performed with a monounsaturated fatty acid (OA) in the presence 
of high glucose, which minimizes inflammatory lipogenic effects. In these 
experiments, metformin decreased intracellular fat contents and activated the 
autophagy machinery. The activation of the autophagy machinery was demonstrated 
on several levels, including examining LC3 turnover in the absence or presence of CQ 
to measure the induction of autophagy, and using fluorescence microscopy to 
visualize autophagosome formation via GFP-LC3 localization. Most importantly, a 
leupeptin-based in vivo animal assay
53
 was applied to assess the dynamics of 
autophagic flux under the in vivo condition, showing that both metformin and CR 
induced autophagic flux in the liver of ob/ob mice. However, considering previous 
reports showing age-related decline in autophagy function in livers,
54-58
 it is quite 
possible that metformin may be less able to alleviate hepatic steatosis in elderly 
human subjects by activation of autophagy.  
Regarding the mechanisms by which CR and metformin unload caloric burden, the 
role of PRKA as a key energy sensor for suppressing lipid accumulation and cell 
growth is well established.
59-63
 In contrast, the MTOR (mechanistic target of 
rapamycin) signaling pathway has been proposed to have an opposing role to PRKA 
55 
 
with respect to protein synthesis, cell growth, and cell division.
64-66
 Inhibition of 
MTOR induces autophagy, a process which plays a homeostatic role not only by 
breaking and removing cellular components, but also by decreasing cellular stores of 
TGs, as demonstrated in this study in hepatocytes.
67,68
 Under low-nutrient conditions, 
increased PRKA activity controls the induction of autophagy by activating either the 
MTOR-ULK1 or the SIRT1-FOXO signaling pathway.
18,19,25,69,70
 In addition, 
metformin activates both PRKA and SIRT1 through a PRKA-mediated increase in 
gene expression of NAMPT (nicotinamide phosphoribosyltransferase), the rate-
limiting enzyme of the salvage pathway for NAD
+
.
29
 In this study, we tested whether 
SIRT1 regulates the autophagic machinery, and whether this regulation required 
PRKA activation; to this end, we used siRNA to manipulate cellular levels of both 
SIRT1 and PRKAA1/2. We observed that both SIRT1 and pPRKA were still 
upregulated upon treatment with metformin even under PRKAA1/2 and SIRT1 
knockdown conditions, respectively. Taken together, we suggest that metformin 
induces SIRT1 gene expression via a PRKA-independent pathway, thereby resulting 
in autophagy induction. 
The present study has some limitations, which should be addressed by further 
research. Although it is well known that autophagic activation induces lipophagy, 
which leads to decreased cellular lipid content, we did not demonstrate direct 
evidence of lipophagy as a link between increased autophagic flux by metformin and 
reduced lipid accumulation in hepatocytes. Moreover, additional experiments with 
genetically engineered animal models such as liver-specific Atg7- or Sirt1-knockout 
mice should be conducted in the future to provide a more definitive mechanistic role 
of metformin. 
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Regarding autophagy-induced clearance of hepatic fat content, metformin was no 
longer able to alleviate lipid accumulation either in the presence of an inhibitor of 
autophagy, 3MA, or upon siRNA-mediated knockdown of ATG5, an important player 
in the elongation step of autophagosome formation. In addition, overexpression of 
SIRT1 stimulated induction of autophagy, thereby alleviating the increase in hepatic 
fat content normally caused by OA.  Furthermore, the TG-lowering action of SIRT1 
was also abolished by incubation with 3MA.  Collectively, these data suggest that 
metformin-mediated alleviation of increased hepatic fat content involves the 
autophagy machinery, a finding that may have implications for the pathogenesis and 
treatment of hepatosteatosis. 
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V. CONCLUSION 
 
Taken together our results suggest that metformin apparently improved the 
hepatosetatosis. These beneficial effects are thought to be related with SIRT-mediated 
autophagy induction via a PRKA-independent pathway.  
However, further studies with genetically engineered animal models such as liver-
specific Atg7- or Sirt1-knockout mice are necessary to elucidate the definitive 
mechanistic role of metformin.  
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Abstract (in Korean) 
 
 
Metformin의 Sirt1-autophay 활성화를 통한 지방간 개선 
 
 
<지도교수 차 봉 수> 
 
 
연세대학교 대학원 의과학과 
 
 
송 영 미 
 
 
자가포식작용 (Autophagy) 활성화 감소에 의한 외부 
스트레스에 대한 방어 기전 억제는 불안정 세포 항상성을 의미한다. 
억제된 자가포식작용의 활성화가 지방간을 호전 시킨다는 기존의 
연구를 바탕으로 „자가포식작용 활성화가 지방간의 새로운 
치료기전’으로 연구가 진행되고 있다. 임상적으로 칼로리 제한은 
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지방간을 호전 시키며, 이러한 기전으로 SIRT1 의 증가에 의한 
자가포식작용 유도가 그 기전으로 제시되었다. 메트포민은 PARK, 
SIRT1 모두를 활성화 시킬 수 있으며, 앞서 언급했듯이 
자가포식작용은 PRKA-MTOR-ULK1 또는 SIRT1-FOXO 를 통해 
유도된다. 본 연구에서는 SIRT1, PRKA 와 자가포식작용의 상호작용 
연구를 통하여 메트포민의 지방간 완화 메커니즘을 설명하고자 한다. 
이를 위하여 ob/ob 쥐를 대조군 (자유식), 300 mg/kg 메트포민을 
복강을 통해 주사한 군 (자유식), 식이 제한 군 (3 g/day)으로 나누어 
4주 동안 유지하였다.  
또한, 일차배양 간세포와 HepG2 세포는 올레산과 고농도 포도당을 
처리한 그룹, 올레산과 고농도 포도당이 있는 세포에 메트포민을 
함께 처리한 그룹으로 나누어 비교하였다.  
식이 제한 군과 메트포민 처리한 군의 ob/ob 쥐의 몸무게, 포도당 
항상성, 지방간이 향상 되었다. 또한, SIRT1과 자가포식작용이 
증가하였다. 
생체 외 실험에서 메트포민이 올레산과 고농도 포도당처리에 의한 
SIRT1과 자가포식작용의 발현 억제를 막는 것을 확인하였다. 지방 
축적 또한 메트포민에 의해 개선됨을 관찰 하였다.  
마지막으로 siRNA를 통한 PRKAA1/2를 억제 시켰을 때도 
메트포민에 의한 SIRT1의 발현은 유지 되었고, 또한 SIRT1이 억제 
71 
 
되었을때도 phospho-PRKA의  발현이 유지 되었다.  
결론적으로 메트포민이 PRKA를 거치지 않고 SIRT1을 통해 
자가포식작용을 유도하여 지방간을 완화 시킬 수 있음을 제시한다.  
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